Focus on human microbiome to fight liver cirrhosis

22 European institutions join forces in MICROB-PREDICT to improve the prevention and treatment of chronic liver disease (cirrhosis). We aim to identify microbiome-based biomarkers and mechanisms that predict in advance when the body can no longer compensate for the dysfunctional liver (decompensated cirrhosis), when such decompensated cirrhosis will progress to acute-on-chronic liver failure (ACLF), and a patient’s individual treatment response. Based on such biomarkers, we strive to develop novel diagnostic tools for earlier and better patient stratification and to establish personalised and effective treatment strategies.

Learn more

EASL School on Hepatology 2020 in Frankfurt

Management of acute-on-chronic liver failure
Location: Goethe University Frankfurt
Date: 03.- 04.07.2020
Course director: Prof. Jonel Trebicka
More information

More news

Copenhagen, 11 September 2019

The MICROB-PREDICT Steering Committee met for the second time in Copenhagen. We are happy to summarize that the project is ahead of schedule.

More events